Chimeric chains for receptor-associated signal transduction pathways
First Claim
1. A method for treating a viral disease or a malignancy in a mammal, wherein cells of said mammal express viral or tumor antigens, comprising introducing modified T cells into said mammal wherein said modified T cells comprise a chimeric DNA encoding a membrane bound protein comprising in the N-terminal to C-terminal direction:
- a single chain antibody domain that binds specifically to said viral or tumor antigen;
a transmembrane domain; and
a cytoplasmic signal-transducing domain obtained from ζ
wherein when said single chain antibody domain binds to said viral or tumor antigen on said cell, said modified T cells kill the cells expressing said viral or tumor antigen.
3 Assignments
0 Petitions
Reexamination
Accused Products
Abstract
Chimeric proteins and DNA encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.
90 Citations
2 Claims
-
1. A method for treating a viral disease or a malignancy in a mammal, wherein cells of said mammal express viral or tumor antigens, comprising introducing modified T cells into said mammal wherein said modified T cells comprise a chimeric DNA encoding a membrane bound protein comprising in the N-terminal to C-terminal direction:
-
a single chain antibody domain that binds specifically to said viral or tumor antigen;
a transmembrane domain; and
a cytoplasmic signal-transducing domain obtained from ζ
wherein when said single chain antibody domain binds to said viral or tumor antigen on said cell, said modified T cells kill the cells expressing said viral or tumor antigen.- View Dependent Claims (2)
-
Specification
-
- Resources
-
Current AssigneeANI Pharmaceuticals, Inc.
-
Original AssigneeCell Genesys Incorporated (ANI Pharmaceuticals, Inc.)
-
InventorsZsebo, Krisztina, Capon, Daniel J., Weiss, Arthur, Roberts, Margo R., Irving, Brian A.
-
Primary Examiner(s)Martin, Jill D.
-
Application NumberUS08/479,737Time in Patent Office2,358 DaysField of Search514/44, 424/93.21, 536/23.4, 435/69.1, 435/240.1, 435/240.2, 435/320.1, 435/69.5, 435/455, 435/325US Class Current424/93.21CPC Class CodesC07K 14/7051 T-cell receptor (TcR)-CD3 c...C07K 14/70514 CD4C07K 14/70535 Fc-receptors, e.g. CD16, CD...C07K 2319/00 Fusion polypeptide
